Several other analysts also recently commented on the company. ValuEngine raised Karyopharm Therapeutics from a sell rating to a hold rating in a research note on Monday, April 1st. Zacks Investment Research downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a research note on Saturday, March 2nd. JPMorgan Chase & Co. downgraded Karyopharm Therapeutics from an overweight rating to a neutral rating and reduced their price objective for the company from $21.00 to $7.00 in a research note on Friday, March 1st. Bank of America downgraded Karyopharm Therapeutics from a neutral rating to an underperform rating and reduced their price objective for the company from $15.00 to $5.00 in a research note on Wednesday, February 27th. Finally, HC Wainwright reaffirmed a buy rating on shares of Karyopharm Therapeutics in a research note on Wednesday, February 27th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. Karyopharm Therapeutics presently has a consensus rating of Hold and a consensus target price of $17.75.
Karyopharm Therapeutics stock opened at $5.89 on Friday. Karyopharm Therapeutics has a fifty-two week low of $3.92 and a fifty-two week high of $21.71. The company has a debt-to-equity ratio of 0.98, a current ratio of 6.19 and a quick ratio of 6.19. The stock has a market cap of $385.85 million, a P/E ratio of -1.88 and a beta of 2.62. The firm has a 50-day moving average price of $5.48.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.75 million. Sell-side analysts forecast that Karyopharm Therapeutics will post -3.81 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers raised its position in shares of Karyopharm Therapeutics by 119.9% in the 4th quarter. Rhumbline Advisers now owns 93,819 shares of the company’s stock worth $879,000 after purchasing an additional 51,163 shares during the last quarter. Prudential Financial Inc. raised its position in shares of Karyopharm Therapeutics by 233.9% in the 4th quarter. Prudential Financial Inc. now owns 73,530 shares of the company’s stock worth $689,000 after purchasing an additional 51,510 shares during the last quarter. First Trust Advisors LP purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter worth about $1,576,000. PNC Financial Services Group Inc. raised its position in shares of Karyopharm Therapeutics by 660.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock worth $36,000 after purchasing an additional 3,300 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Karyopharm Therapeutics by 391.0% in the 4th quarter. California Public Employees Retirement System now owns 165,746 shares of the company’s stock worth $1,553,000 after purchasing an additional 131,986 shares during the last quarter. 84.20% of the stock is owned by hedge funds and other institutional investors.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Further Reading: Outstanding Shares
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.